Watch ImStem’s scientists introduce its innovative stem cell technology on Bloomberg
The first US patient has been dosed with an investigational stem cell therapy called IMS001, for multiple sclerosis (MS), developed by ImStem Biotechnology.
ImStem Biotechnology today announces the dosing of the first US multiple sclerosis patient with its lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.
UConn TIP company ImSTEM Biotechnology is conducting a clinical trial to test their experimental human embryonic stem cell-derived mesenchymal stem cell therapy for the treatment of multiple sclerosis.